It is not intended for human use, animal use, medical use, diagnostic use, therapeutic use, dietary use, cosmetic use, injection, ingestion, inhalation, or topical application
Request for unlocking the Sample Page of the GLP-1 agonists Market DelveInsights Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape and Market Forecast - 2036 report delivers an in-depth understanding of Glucagon-like Peptide-1 (GLP-1) Agonists, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan
The study did not meet the primary endpoint of change on a measure of how much sugar the brain uses for energy, but it showed that patients on the drug had nearly 50% less shrinking in parts of the brain that control memory and learning and that treated participants had a slightly slower decline in cognitive function
[PMID: 288853] PubMed record related to this compound for laboratory literature review